Retatrutide

Product

Last mentioned: Feb 24, 2026

Timeline

  1. Regulatory Submissions

    Expected window for the first triple-agonist drug applications to the FDA.

  2. Phase 3 Expansion

    Anticipated start of Novo Nordisk's pivotal late-stage clinical program.

  3. Novo Triple-G Phase 2

    Novo Nordisk reports nearly 20% weight loss at 26 weeks.

  4. Lilly Retatrutide Phase 2

    Eli Lilly releases data showing 17.5% weight loss at 24 weeks.

Stories mentioning Retatrutide 1

market-trends Neutral

Novo Nordisk Triple-G Agonist Challenges Eli Lilly in Obesity Market

Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.

2 sources